RxDoctor Payments Data

Samrat Khanna, MD

Pulmonary Disease · Kankakee, ILNPI 1053629881

Payments from drug & device makers

$20,762in general payments, 2019–2025

Across 690 payments — averaging $30.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • GSK$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$1K
  • Jazz Pharmaceuticals Inc.$830
  • Mylan Specialty L.p.$648
  • plus $6K from 43 others

What the payments were for

  • Travel & lodging$7364%
  • Food & beverage$12,75861%
  • Education$7,26835%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,762 in reported general payments places this provider in the 85th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$227,660
Medicare patients
911
Services billed
2,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter417$337,653
Breo ElliptaFluticasone/Vilanterol152$66,545
Breztri AerosphereBudesonide/Glycopyr/Formoterol62$49,256
Spiriva RespimatTiotropium Bromide51$30,124
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$27,361
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$25,939
Advair HfaFluticasone Propion/Salmeterol48$19,141
EliquisApixaban21$16,065
SymbicortBudesonide/Formoterol Fumarate38$15,337
Spiriva HandihalerTiotropium Bromide12$15,009
Albuterol Sulfate HfaAlbuterol Sulfate389$13,155
Incruse ElliptaUmeclidinium Bromide31$10,097
Arnuity ElliptaFluticasone Furoate29$7,864
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$6,854
Ventolin HfaAlbuterol Sulfate94$6,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,464$449,521679 claims
AstraZenecaBreztri Aerosphere, Symbicort, Airsupra$2,041$70,348113 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,147$56,06384 claims
PfizerEliquis$46$16,06521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Kankakee

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →